Drugs

Treatment for Pulmonary Arterial Hypertension (PAH) Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension RESEARCH TRIANGLE PARK, N.C., Nov. 25, 2020 (GLOBE NEWSWIRE) – Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation (NASDAQ: LQDA), today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response
0 Comments
December 2, 2020 Audience: Consumer, Patient, Health Professional, Pharmacy December 2, 2020 — Mesquite, TX MPM Medical is voluntarily recalling one lot of Regenecare HA Hydrogel to the consumer level. Following two customer complaints of visible contamination, the product was found to be contaminated with the bacteria Burkholderia cepecia. Risk Statement: Topical application of Regenecare
0 Comments
New study suggests reproductive hormones may play a protective role against COVID. As of August 2020, worldwide deaths due to COVID-19 totaled over 770,000. However, the virus does not randomly pick its victims. Certain risk factors make a person more likely to suffer or even die from a severe case of COVID-19. Researchers continue to
0 Comments
Brain Damage in COVID Patients It is now clear that in addition to respiratory symptoms, COVID-19 also affects other parts of the body, with neurological symptoms also reported – such as the most well-known, loss of smell. A study published in the American Journal of Neuroradiology has reported on the results of an imaging study
0 Comments
FDA Approves Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration
0 Comments
FDA Approves Imcivree (setmelanotide) for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency BOSTON, Nov. 27, 2020 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, announced today that the U.S. Food &
0 Comments
A recent study presents a new metric for predicting COVID-19 outcomes. As the world grapples with the ongoing COVID-19 pandemic, advancements in research bring clarity, promise, and hope in managing this crisis. Of late, a group of researchers from the Royal College of Surgeons in Ireland, created a prognostic point system capable of predicting COVID-19
0 Comments
ATLANTA, Nov. 17, 2020 /PRNewswire/ — UCB, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Vimpat (lacosamide) CV as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older and Vimpat injection for intravenous use in children four
0 Comments
Researchers recently studied the effect of age on weight loss efforts. The obesity epidemic currently affects over 300 million people around the world. Even developing nations suffer with as many as 115 million people classified as obese. Obesity is related to many other diseases, such as heart disease, high blood pressure, diabetes, stroke, and even
0 Comments
South San Francisco, CA — November 23, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and
0 Comments
New research develops vital animal model of SARS-CoV-2 to help identify the key features of infection. The development of effective therapies to treat COVID-19 is a problem of immense global significance. However, one of the key steps in the development of a novel therapeutic is the development of a reliable animal model that can be
0 Comments
FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 24, 2020– Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved Oxlumo (lumasiran) injection for subcutaneous use, the first-ever therapy available for the treatment of primary hyperoxaluria type 1
0 Comments
A recent study demonstrated that Google search trends could help in predicting COVID-19 hot spots.   Web-based activity detection tools can play an important role in the early detection of infectious diseases. These internet search behaviour tools may also help in the timely preparedness of health care systems to avoid the adverse consequences of being
0 Comments
Researchers are investigating the potential of the broad spectrum anti-microbial ivermectin for COVID-19 treatment. As the COVID-19 pandemic, caused by the SARS-CoV-2 virus, continues to spread around the world, researchers are looking for candidate drugs to use as potential therapies. Repurposing drugs already in use for other infections could allow a quicker route to finding
0 Comments
20 November 2020 –  AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy (CRT) and previously treated advanced bladder cancer. This new option is consistent with the
0 Comments
November 19, 2020 Audience: Consumer, Patient, Health Professional, Pharmacy November 19, 2020 — Fresenius Kabi USA is voluntarily recalling a single lot of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg/50 mL (4 mcg /mL), 50 mL fill in a 50 mL vial. Fresenius Kabi initiated this recall due to a trace amount of
0 Comments
A new research study detects pre-existing antibody-driven immunity against SARS-CoV-2 in some individuals, with higher rates in uninfected children. Different age groups appear to have different responses to COVID-19, with kids often presenting with mild or no symptoms. However, the reason for this remains relatively unclear.  Although COVID-19 is at the forefront of the news
0 Comments
FDA Approves Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Zokinvy (lonafarnib) for the
0 Comments
A recent study examined the underlying genetic association between inflammation, metabolic dysregulation, and depressive symptoms. Researchers have been trying to understand what causes mental illness, and how it develops for many decades. In recent years, scientists have been better able to sequences the genomes of people, and look for associations between certain psychological illnesses and
0 Comments
Conservative and natural treatments for pink eye are the most sensible approaches. Conjunctivitis, also known as pink eye, is the inflammation of the eye’s transparent covering caused by viruses, bacteria, pollen, dust, pet dander, smoke and pollutants. Viruses and bacteria are the most frequent suspects in infective conjunctivitis. Viral conjunctivitis is more common than bacterial
0 Comments
Research indicates a possible link between sleep apnea and COVID-19 risk. In the United States, more than 18 million people suffer from sleep apnea, a disorder that makes it difficult to breathe while sleeping. Sleep apnea can lead to poor sleep hygiene and has also been linked to obesity, heart disease, hypertension, and teeth grinding.
0 Comments
vosoritide Treatment for Achondroplasia FDA Accepts BioMarin’s New Drug Application for Vosoritide to Treat Children with Achondroplasia SAN RAFAEL, Calif., Nov. 2, 2020 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vosoritide, an investigational, once daily injection analog of C-type
0 Comments
A recent study reports on the beneficial effects of a new inhalable COVID-19 treatment. Coronavirus disease 19 (COVID-19) originated in Wuhan, China December of 2019 and has since turned into a pandemic. As this rapidly growing health crisis has swept over the globe, it has affected 4 million people and caused 283,000 deaths in over
0 Comments
Treatment for Postoperative Pain Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain SAN DIEGO, Nov. 13, 2020 /PRNewswire/ – Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced
0 Comments